Clinical Trials Browser

Locally Recurrent Rectal Cancer × Cetuximab × 1 year × Clear all

NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Phase 2 Recruiting

Gastrointestinal

Locally Recurrent Rectal Cancer